Lanreotide improves survival with enteropancreatic tumors

July 21, 2014
Lanreotide improves survival with enteropancreatic tumors

(HealthDay)—Lanreotide significantly improves survival among patients with metastatic enteropancreatic neuroendocrine tumors (grade 1 or 2), according to a study published in the July 17 issue of the New England Journal of Medicine.

Martyn E. Caplin, D.M., from Royal Free Hospital in London, and colleagues conducted a multinational study of with advanced, well-differentiated or moderately-differentiated, nonfunctioning, somatostatin receptor-positive neuroendocrine tumors (grade 1 or 2 that originated in the pancreas, midgut, or hindgut, or were of unknown origin) and documented disease-progression status. Participants were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide at a dose of 120 mg (101 patients) or placebo (103 patients) once every 28 days for 96 weeks.

The researchers found that, compared to placebo, lanreotide was associated with significantly prolonged progression-free (P < 0.001; hazard ratio for progression or death, 0.47). At 24 months, the estimated rates of progression-free survival were 65.1 percent in the lanreotide group and 33.0 percent in the group. In predefined subgroups, the therapeutic effect was generally consistent with that found in the overall population. Groups were similar in quality of life and overall survival. Diarrhea was the most common treatment-related adverse event (26 percent of the lanreotide group versus 9 percent of the ).

"Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic of grade 1 or 2 (Ki67 < 10 percent)," the authors write.

The study was funded by Ipsen, the manufacturer of lanreotide.

More information: Full Text (subscription or payment may be required)

Related Stories

Abiraterone benefits chemo-naive with advanced prostate CA

December 12, 2012

(HealthDay)—For chemotherapy-naive patients with metastatic castration-resistant prostate cancer, abiraterone acetate correlates with improved radiographic progression-free survival, according to a study published online ...

Study compares survival for treatments of uncommon eye cancer

June 17, 2014

In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall ...

Survival up after progression in HPV-positive oropharynx CA

June 26, 2014

(HealthDay)—For patients with oropharynx cancer (OPC), human papillomavirus (HPV) positivity is associated with improved survival after disease progression, according to a study published online June 23 in the Journal of ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Exciting results from cancer immunoagent study

July 20, 2015

(Medical Xpress)—Cancer therapies have improved incrementally over the years, but cancer treatment largely remains analogous to forest fire suppression, in which the spread of fire is contained with deliberate controlled ...

Modified DNA building blocks are cancer's Achilles heel

July 22, 2015

In studying how cells recycle the building blocks of DNA, Ludwig Cancer Research scientists have discovered a potential therapeutic strategy for cancer. They found that normal cells have highly selective mechanisms to ensure ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.